ONGOING INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
New York, New York--(Newsfile Corp. - June 14, 2024) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is investigating whether certain dir
H.C. Wainwright Maintains Ventyx Biosciences(VTYX.US) With Hold Rating, Maintains Target Price $6
H.C. Wainwright analyst Emily Bodnar maintains $Ventyx Biosciences(VTYX.US)$ with a hold rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 39.3
Express News | HC Wainwright & Co. Reiterates Neutral on Ventyx Biosciences, Maintains $6 Price Target
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates Ventyx Biosciences, Inc.'s Directors and Officers for Breach of Fiduciary Duties - VTYX
New York, New York--(Newsfile Corp. - June 11, 2024) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, is investigating whether certain dir
Ventyx Biosciences Insider Sellers Vindicated After 32% Drop
Insiders seem to have made the most of their holdings by selling US$222k worth of Ventyx Biosciences, Inc. (NASDAQ:VTYX) stock at an average sell price of US$2.44 during the past year. The company's
Oppenheimer Maintains Ventyx Biosciences(VTYX.US) With Buy Rating, Cuts Target Price to $10
Oppenheimer analyst Jeff Jones maintains $Ventyx Biosciences(VTYX.US)$ with a buy rating, and adjusts the target price from $12 to $10.According to TipRanks data, the analyst has a success rate of 40.
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.G-III Apparel Group posted adjusted earn
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersVirax Biolabs Group (NASDAQ:VRAX) shares rose 88.8% to $2.02 during Thursday's regular session. The company's market cap stands at $4.7 million. FibroBiologics (NASDAQ:FBLG) shares rose 45.37%
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday.The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 50
Ventyx Biosciences Is Maintained at Outperform by Oppenheimer
Ventyx Biosciences Is Maintained at Outperform by Oppenheimer
Oppenheimer Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $10
Oppenheimer analyst Jeff Jones maintains Ventyx Biosciences (NASDAQ:VTYX) with a Outperform and lowers the price target from $12 to $10.
A Quick Look at Today's Ratings for Ventyx Biosciences(VTYX.US), With a Forecast Between $6 to $21
On Jun 06, major Wall Street analysts update their ratings for $Ventyx Biosciences(VTYX.US)$, with price targets ranging from $6 to $21.Wells Fargo analyst Derek Archila maintains with a buy rating, a
Express News | Ventyx Biosciences : Oppenheimer Cuts Target Price to $10 From $12
Ventyx Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/06/2024 12.15% HC Wainwright & Co. $6 → $6 Reiterates Neutral → Neutral 03/13/2024 180.37% Canaccord Ge
Ventyx Reports Preclinical Results for Anti-obesity Drug VTX3232
Express News | Ventyx Biosciences:Additive Effects Seen for Vtx3232 Combined With GLP-1 Receptor Agonist Semaglutide Across Key Endpoints Vs Semaglutide/Vtx3232 Alone
Express News | Ventyx Biosciences Shares Are Trading Higher After the Company Announced Preclinical Data for Its CNS-penetrant NLRP3 Inhibitor VTX3232 in Murine Diet-induced Obesity Models
Express News | Ventyx Biosciences Inc - Vtx3232 Demonstrated Improvements in Body Weight, Systemic Inflammatory Biomarkers & Cardiometabolic Parameters in Dio Mice
Express News | Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant Nlrp3 Inhibitor Vtx3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
Ventyx Biosciences (VTYX) Receives a Buy From LifeSci Capital
No Data